The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Alwin G SchullerCelina M D'Cruz

Abstract

Papillary renal cell carcinoma (PRCC) is the second most common cancer of the kidney and carries a poor prognosis for patients with nonlocalized disease. The HGF receptor MET plays a central role in PRCC and aberrations, either through mutation, copy number gain, or trisomy of chromosome 7 occurring in the majority of cases. The development of effective therapies in PRCC has been hampered in part by a lack of available preclinical models. We determined the pharmacodynamic and antitumor response of the selective MET inhibitor AZD6094 in two PRCC patient-derived xenograft (PDX) models. Two PRCC PDX models were identified and MET mutation status and copy number determined. Pharmacodynamic and antitumor activity of AZD6094 was tested using a dose response up to 25 mg/kg daily, representing clinically achievable exposures, and compared with the activity of the RCC standard-of-care sunitinib (in RCC43b) or the multikinase inhibitor crizotinib (in RCC47). AZD6094 treatment resulted in tumor regressions, whereas sunitinib or crizotinib resulted in unsustained growth inhibition. Pharmacodynamic analysis of tumors revealed that AZD6094 could robustly suppress pMET and the duration of target inhibition was dose related. AZD6094 inhibited ...Continue Reading

References

Jan 1, 1993·Advances in Cancer Research·G Kovacs
Dec 20, 2003·Nature Reviews. Molecular Cell Biology·Carmen BirchmeierGeorge F Vande Woude
Jun 14, 2005·Trends in Molecular Medicine·Simona CorsoSilvia Giordano
Oct 7, 2008·The Cancer Journal·Wong-Ho Chow, Susan S Devesa
Jun 6, 2009·Expert Review of Anticancer Therapy·Alessio GiubellinoDonald P Bottaro
Jul 21, 2009·The Lancet Oncology·Martin E GoreRonald Bukowski
Oct 19, 2010·Cancer Research·Farbod ShojaeiJames G Christensen
Nov 26, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Shinji YamazakiTatiana Koudriakova
Mar 23, 2011·Oncogene·A M DulakJ M Siegfried
Jan 25, 2012·Nature Reviews. Cancer·Ermanno GherardiGeorge Vande Woude
Dec 6, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Toni K ChoueiriRamaprasad Srinivasan
Apr 24, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jennifer R DiamondD Ross Camidge
May 21, 2013·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Andrew Timm, Jill M Kolesar
Mar 25, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Laurence AlbigesBernard Escudier
Jun 11, 2014·Molecular Oncology·Beth O Van EmburghAlberto Bardelli
Oct 24, 2014·Biomedicines·Luigi Ruco, Stefania Scarpino

❮ Previous
Next ❯

Citations

Jan 1, 2015·PeerJ·Jordan AnayaAnindya Dutta
Sep 4, 2016·Journal of Translational Medicine·Giulia M StellaSilvia Benvenuti
Oct 23, 2016·Frontiers of Medicine·Shuhang WangDelong Liu
Jan 15, 2017·BMC Urology·Takanobu MotoshimaMasatoshi Eto
Sep 8, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sumanta K PalNeeraj Agarwal
Mar 2, 2017·Nature Reviews. Urology·Takahiro InoueOsamu Ogawa
Jun 24, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Toni K ChoueiriSumanta Kumar Pal
Nov 27, 2018·Expert Review of Anticancer Therapy·Qiwei ChenQuanlin Li
Nov 2, 2018·Archives of Pathology & Laboratory Medicine·Nicole K AndeenMaria S Tretiakova
Aug 14, 2019·Journal of Cellular Biochemistry·Yi Duan, Dong Zhang
Jun 1, 2017·American Society of Clinical Oncology Educational Book·Tian ZhangSumanta K Pal
Sep 27, 2019·Expert Opinion on Investigational Drugs·Lakshminarayanan NandagopalNeeraj Agarwal
Aug 24, 2018·Cancers·Oshin MirandaJill M Siegfried
Nov 15, 2018·Frontiers in Oncology·Francesca GiunchiMichelangelo Fiorentino
Mar 20, 2018·Oncogene·Leslie DuplaquetDavid Tulasne
Oct 12, 2019·Nature Reviews. Urology·Anna BrodziakAnna M Czarnecka
Sep 7, 2018·Journal of Experimental & Clinical Cancer Research : CR·Simona di MartinoDésirée Bonci
Dec 24, 2019·Kidney Cancer·Katherine Emilie Rhoades Smith, Mehmet Asim Bilen
Apr 15, 2020·Cancers·Abdulaziz B Hamid, Ruben C Petreaca
Oct 4, 2016·Cancer Discovery·Magda BahcallGeoffrey R Oxnard
Apr 7, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hui K GanJason D Lickliter
Feb 25, 2020·Translational Oncology·Paweł SobczukAnna M Czarnecka
Mar 25, 2021·Cancer Management and Research·Zhitao LiBingqing Hui
Apr 20, 2021·Therapeutic Advances in Medical Oncology·Hang-Ping YaoMing-Hai Wang
May 25, 2021·American Journal of Physiology. Renal Physiology·Kylee A RosetteBrendan D Looyenga
Jul 16, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kyrollis AttallaA Ari Hakimi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

© 2021 Meta ULC. All rights reserved